Cell Lane Limited

Life Sciences
Aim of funding: 
HMRC Advance Assurance received: 

Cell Lane Limited


Cell Lane Ltd has been established to develop a cell isolation and separation platform technology, based on intellectual property assigned from the University of Leeds. This new technology seeks to assist in the future treatment of chronic diseases such as cancer and AIDS, and is intended to enable new fields of research in research activities such stem cell research. The Company’s proposed technology can be used to rapidly separate cells whilst preserving their functionality and overall viability.

Cell Lane is in the process of developing its technology to a point where it has a Minimum Viable Product (‘MVP’), the MVP (i.e. the new platform) will then be developed and taken forwards to be commercialised by the Company.



Cell Lane Ltd believes that there is a pronounced need to develop new medicines and to vastly improve existing drug therapeutics using the very latest available improvement techniques. There is also a clear medical need to improve production volume outputs to not only lower production costs but to widen access to these drugs in geographical areas such as the developing world, areas in which there is often the greatest need. The very latest and revolutionary cell-based analytic and development technologies can potentially address some of these very real medical needs. 

North America is the largest region in the cell isolation market, followed by Europe, Asia, and the rest of the world  [1]. However, Asia is projected to grow at the highest compounded annual growth rate in the medium term. Factors such as increasing interest from emerging markets, as well as growing government support, and the high prevalence of diseases are driving the growth of this market.

Cell Lane states that the global cell isolation market is expected to reach USD 7.89 Billion by 2021 from USD 3.57 Billion in 2016, at a CAGR of 17.2%  [1]. The cell isolation market is broadly segmented on the basis of product, cell type, production technique, and therapeutic application.  

It is reasonable to propose that the companies that are able to deliver cost-effective, quality-focused and large volume methods for the production of cell therapies will become acquisition or licensing targets by larger pharmaceutical companies.


Information on this webpage relates to and is provided by Deepbridge Advisers Limited.

The content of this webpage should not be construed as financial advice. Any decision to invest should be made only on the basis of the relevant documentation for each investment. Past performance is not necessarily a guide to future performance. The value of an investment may go down as well as up and investors may not get back the full amount invested. Investments in small unquoted companies carry an above-average level of risk. These investments are highly illiquid and as such, there may not be a readily available market to sell such an investment. Deepbridge Capital LLP, Deepbridge Advisers Limited and Enterprise Partners LLP (together "the Sponsors," or "Sponsor) do not provide specific individual advice on the suitability of investments with regard to a potential investor's individual circumstances, risk tolerance or investment objectives and investors should seek independent financial advice if they are in any doubt whether a product is suitable for them.